A Secret Weapon For M3541
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge numerous intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Major demo targets were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyosi